Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Up 75.1% in January

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 41,500 shares, a growth of 75.1% from the January 15th total of 23,700 shares. Based on an average daily volume of 299,700 shares, the days-to-cover ratio is currently 0.1 days. Currently, 2.6% of the shares of the company are sold short.

Sonoma Pharmaceuticals Price Performance

NASDAQ:SNOA traded down $0.03 during midday trading on Thursday, reaching $2.52. 28,405 shares of the company traded hands, compared to its average volume of 49,869. The firm has a market capitalization of $4.07 million, a price-to-earnings ratio of -0.63 and a beta of 1.43. The company has a fifty day moving average price of $2.67 and a 200 day moving average price of $2.44. Sonoma Pharmaceuticals has a twelve month low of $2.44 and a twelve month high of $9.37.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Wednesday, February 5th. The company reported ($0.59) earnings per share (EPS) for the quarter. Sonoma Pharmaceuticals had a negative net margin of 26.82% and a negative return on equity of 68.98%. On average, equities research analysts forecast that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 1.95% of the stock is currently owned by institutional investors and hedge funds.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.